UY35381A - Pirrolotriazinas como inhibidores del canal del ion potasio - Google Patents

Pirrolotriazinas como inhibidores del canal del ion potasio

Info

Publication number
UY35381A
UY35381A UY0001035381A UY35381A UY35381A UY 35381 A UY35381 A UY 35381A UY 0001035381 A UY0001035381 A UY 0001035381A UY 35381 A UY35381 A UY 35381A UY 35381 A UY35381 A UY 35381A
Authority
UY
Uruguay
Prior art keywords
inhibitors
pirrolotriazinas
ion channel
potassium ion
function
Prior art date
Application number
UY0001035381A
Other languages
English (en)
Inventor
Govindrajulu Kavitha
Naveen Kumar Dhondi
Srinivasu Pothukanuri
Finlay Heather
Ashok Kumar Adisechan
Gunaga Prashantha
Lloyd John
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY35381A publication Critical patent/UY35381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la Fórmula I en donde A, R1, R3 y R24 se describen en la presente. Los compuestos son útiles como inhibidores de la función del cana l de potasio y para el tratamiento de la arritmia, manteniendo el ritmo sinusal normal, de los trastornos asociados a IKur- y de otros trastornos me diados por la función del canal iónico.
UY0001035381A 2013-03-11 2014-03-11 Pirrolotriazinas como inhibidores del canal del ion potasio UY35381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775731P 2013-03-11 2013-03-11
US14/200,055 US9050345B2 (en) 2013-03-11 2014-03-07 Pyrrolotriazines as potassium ion channel inhibitors

Publications (1)

Publication Number Publication Date
UY35381A true UY35381A (es) 2014-09-30

Family

ID=51488539

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035381A UY35381A (es) 2013-03-11 2014-03-11 Pirrolotriazinas como inhibidores del canal del ion potasio

Country Status (8)

Country Link
US (1) US9050345B2 (es)
EP (1) EP2970296B1 (es)
JP (1) JP6427551B2 (es)
CN (1) CN105008367B (es)
AR (1) AR095208A1 (es)
TW (1) TW201444847A (es)
UY (1) UY35381A (es)
WO (1) WO2014143610A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150228A1 (es) * 2012-06-11 2015-02-19 Bristol Myers Squibb Co Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida
JP2016516691A (ja) 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのイソキノリン
US9458164B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
WO2014143606A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US10292985B2 (en) 2015-08-31 2019-05-21 Bristol-Myers Squibb Company TGF beta receptor antagonists
CN105111154A (zh) * 2015-09-15 2015-12-02 上海瑞博化学有限公司 一种5-氨基吡嗪-2-甲酸合成新工艺
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為ｔａｍ抑制劑之吡咯并三嗪化合物
US10577382B2 (en) 2016-04-28 2020-03-03 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP3619222A4 (en) 2017-05-05 2021-02-17 Nino Sorgente METHODS AND COMPOSITIONS FOR IMPROVING EYE HEALTH
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
EP4331679A3 (en) 2017-06-21 2024-04-03 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
MX2023005436A (es) * 2020-11-10 2023-07-25 Foghorn Therapeutics Inc Compuestos y usos de estos.
CN116063183B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种环丙胺的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
RU2001103044A (ru) 1998-07-06 2003-08-10 Бристол-Маерс Сквибб Ко. (Us) Бенилсульфонамиды в качестве двойных антагонистов ангиотензиновых эндотелиновых рецепторов
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
NZ525334A (en) * 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1543009A4 (en) 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazine KINASE INHIBITORS
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
KR20050099525A (ko) 2003-02-05 2005-10-13 브리스톨-마이어스 스큅 컴퍼니 피롤로트리아진 키나제 억제제의 제조 방법
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
EP1799218A1 (en) 2004-09-30 2007-06-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101395158A (zh) 2006-03-07 2009-03-25 百时美施贵宝公司 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
PL2041138T3 (pl) 2006-07-07 2014-11-28 Bristol Myers Squibb Co Pirolotriazyny jako inhibitory kinazy
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2008131050A1 (en) 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2009026254A1 (en) 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
DE102007051762A1 (de) * 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
EP2262806A1 (en) 2008-03-06 2010-12-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20110269740A1 (en) 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
CN102245610B (zh) * 2008-10-08 2014-04-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
MY160243A (en) * 2009-09-03 2017-02-28 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
PE20150228A1 (es) * 2012-06-11 2015-02-19 Bristol Myers Squibb Co Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida

Also Published As

Publication number Publication date
JP2016512505A (ja) 2016-04-28
US20140256719A1 (en) 2014-09-11
CN105008367A (zh) 2015-10-28
EP2970296A1 (en) 2016-01-20
US9050345B2 (en) 2015-06-09
AR095208A1 (es) 2015-09-30
WO2014143610A1 (en) 2014-09-18
EP2970296B1 (en) 2016-12-21
TW201444847A (zh) 2014-12-01
JP6427551B2 (ja) 2018-11-21
CN105008367B (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CU24414B1 (es) Lactamas n-(heteroarilo sustituido) fusionadas útiles en el tratamiento del crecimiento celular anormal
CU20170056A7 (es) Métodos para tratar infecciones por el virus filoviridae
UY34648A (es) Amidas como inhibidores de pim
NI201500112A (es) Compuestos de azabencimidazol como inhibidores de isozimas pde4 para el tratamiento del snc y otros trastornos.
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
UY35630A (es) Carboxamidas primarias como inhibidores de btk
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34171A (es) Compuestos heterocíclicos fusionados como moduladores del canal iónico
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
CR20120448A (es) Compuesto heterocíclico
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CL2018002583A1 (es) Derivado de morfolina
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
BR112017009289A2 (pt) métodos de administrar composições de amantadina
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.